Lyme Disease Treatment: Antibiotics, Integrative Options, and What to Do When You’re Not Getting Better

How Lyme Disease Is Treated: The Standard Approach

Lyme disease treatment is one of those topics where conventional medicine and integrative medicine see the same patients and reach very different conclusions. If you’re newly diagnosed with an expanding erythema migrans rash and a tick bite you remember, the path forward is straightforward. If you’ve been sick for months with a constellation of symptoms and a complicated test history, the path gets much less clear.

Let’s start with what everyone agrees on.

First-Line Antibiotics for Early Lyme Disease

For early localized and early disseminated Lyme disease, the Infectious Diseases Society of America (IDSA), the American Academy of Neurology, and the American College of Rheumatology jointly updated treatment guidelines in 2020. The primary options are [1]:

• Doxycycline: 100 mg twice daily for 10-21 days. This is the preferred choice for adults because it also covers Anaplasma, a common co-infection transmitted by the same tick. It’s effective for early Lyme with or without facial nerve palsy.
• Amoxicillin: 500 mg three times daily for 14-21 days. Used for children under 8, pregnant or breastfeeding women, and patients who can’t tolerate doxycycline.
• Cefuroxime axetil: 500 mg twice daily for 14-21 days. The second-line alternative when both doxycycline and amoxicillin are contraindicated.

When treatment starts within the first few weeks of infection, the success rate is high. A prospective study following patients treated for early Lyme found that approximately 85-90% had complete resolution of symptoms within 6 months of completing antibiotics [2].

Treatment Duration Debates

The recommended course length has been a point of contention. The 2020 IDSA/AAN/ACR guidelines shortened the minimum doxycycline course to 10 days for uncomplicated erythema migrans, based on evidence showing equivalent outcomes compared to longer courses [1]. Many clinicians, particularly those in integrative or Lyme-literate practice, prefer 21-28 days, arguing that shorter courses risk undertreating a spirochetal infection known for its ability to evade the immune system.

The International Lyme and Associated Diseases Society (ILADS) recommends 4-6 weeks for initial treatment, with individualized extension based on clinical response [3]. This difference in approach represents a genuine disagreement about the biology of Borrelia burgdorferi and what constitutes adequate treatment.

Late-Stage Lyme Disease: When the Diagnosis Comes Late

When Lyme disease is not caught early, it can progress to affect the joints, nervous system, and heart. Each manifestation requires a different treatment strategy.

Lyme Arthritis

Lyme arthritis, the most common late manifestation, typically presents as intermittent or persistent swelling of one or more large joints, most often the knee. The initial treatment is a 28-day course of oral doxycycline or amoxicillin. About 90% of patients respond to one or two courses of oral antibiotics [4].

A subset of patients develops antibiotic-refractory Lyme arthritis, where joint inflammation persists despite adequate antibiotic therapy. This appears to be driven by an autoimmune mechanism rather than ongoing infection. Treatment shifts to disease-modifying antirheumatic drugs (DMARDs) like methotrexate or hydroxychloroquine, and in some cases, TNF-alpha inhibitors [4].

Neurological Lyme Disease

Lyme neuroborreliosis can cause meningitis, cranial nerve palsies (especially facial nerve palsy), radiculopathy, and encephalopathy. IV ceftriaxone (2 grams daily for 14-28 days) has long been the standard for most neurological manifestations. However, recent European data suggests that oral doxycycline may be equally effective for many cases of neuroborreliosis, particularly facial nerve palsy and meningitis without parenchymal brain involvement [5].

The 2020 guidelines now allow oral doxycycline as an option for patients with cranial nerve palsy or meningitis without parenchymal involvement. IV ceftriaxone remains the recommendation for patients with parenchymal central nervous system involvement (encephalomyelitis) [1].

Lyme Carditis

Lyme carditis occurs when the spirochete infects heart tissue, causing varying degrees of atrioventricular (AV) block. Patients with first-degree AV block and a PR interval under 300 milliseconds are typically treated with oral antibiotics. More advanced heart block (second or third degree) requires hospitalization, IV ceftriaxone, and temporary cardiac pacing in severe cases [6].

The good news: Lyme carditis almost always resolves completely with appropriate antibiotic treatment. Permanent pacemaker implantation is rarely needed.

Post-Treatment Lyme Disease Syndrome (PTLDS)

This is where the conversation gets complicated. An estimated 10-20% of patients treated for Lyme disease continue to experience significant symptoms after completing standard antibiotic therapy. The most common persistent symptoms are fatigue, musculoskeletal pain, and cognitive difficulties, particularly problems with short-term memory and word-finding [7].

The conventional explanation, supported by IDSA, is that these symptoms represent a post-infectious immune dysregulation or autoimmune process rather than active infection. The ILADS perspective holds that persistent infection with Borrelia burgdorferi can survive standard antibiotic courses in some patients, citing in vitro studies showing antibiotic-tolerant “persister” forms of the bacteria [8].

A landmark Johns Hopkins study identified persister forms of Borrelia that survive standard antibiotic exposure in the laboratory. These stationary-phase bacteria were not killed by doxycycline or amoxicillin alone but were susceptible to certain drug combinations, including daptomycin plus doxycycline plus cefoperazone [8]. Whether these findings translate to human clinical practice remains an open and actively studied question.

Extended Antibiotic Therapy: What the Trials Show

Four randomized controlled trials have examined prolonged IV and oral antibiotic therapy for PTLDS. The results have been mixed:

• The Klempner et al. trial (2001) found no benefit of IV ceftriaxone followed by oral doxycycline compared to placebo [9].
• The Krupp et al. trial (2003) found that IV ceftriaxone improved fatigue severity compared to placebo, but the benefit was modest and came with a risk of serious adverse events including biliary complications [10].
• The Fallon et al. trial (2008) showed short-term cognitive improvement with IV ceftriaxone that was not sustained at 6 months [11].
• A Dutch trial (Berende et al., 2016) compared longer-term doxycycline, clarithromycin with hydroxychloroquine, and placebo. No significant differences were found between groups [12].

Based on these results, the IDSA recommends against prolonged antibiotic therapy for PTLDS. Many integrative and Lyme-literate practitioners disagree, pointing to the trials’ small sample sizes, patient selection issues, and the fact that Borrelia persister biology wasn’t understood when most of these trials were designed.

Integrative and Herbal Approaches

A growing number of patients and practitioners turn to herbal and integrative therapies, either as adjuncts to antibiotics or as alternatives when antibiotics haven’t worked.

The Buhner Protocol

Herbalist Stephen Harrod Buhner developed a widely used botanical protocol based on plants with documented antimicrobial, anti-inflammatory, and immune-modulating properties. Core herbs include:

• Japanese knotweed (Polygonum cuspidatum): Contains resveratrol and emodin. Buhner proposed it as the primary herb for Borrelia based on its broad antimicrobial activity and ability to cross the blood-brain barrier.
• Cat’s claw (Uncaria tomentosa): Used for immune modulation and anti-inflammatory effects.
• Andrographis: An antimicrobial herb with activity against spirochetes in vitro.
• Cryptolepis: Used primarily for Babesia co-infection.

A 2020 Johns Hopkins in vitro study tested several botanical medicines against Borrelia burgdorferi and found that extracts of Cryptolepis sanguinolenta, Juglans nigra (black walnut), Polygonum cuspidatum (Japanese knotweed), and others had significant activity against both growing and persister forms of the bacteria. Cryptolepis showed the strongest activity, outperforming doxycycline and cefuroxime in eradicating stationary-phase Borrelia [13].

This is a laboratory study, not a clinical trial in humans. But it provides a scientific rationale for botanical approaches and has prompted calls for clinical trials.

The Zhang Protocol

Dr. Qingcai Zhang, a physician trained in both Western and traditional Chinese medicine, developed an herbal protocol combining multiple botanical formulations. His approach targets Borrelia and common co-infections with different herbal combinations. Some practitioners combine Zhang’s herbs with conventional antibiotics in a pulsed regimen.

Other Integrative Approaches

• IV therapy: High-dose IV vitamin C, glutathione, and phosphatidylcholine are used by many integrative Lyme practitioners to support detoxification and reduce oxidative stress. Clinical trial data specifically for Lyme is limited, but these therapies are generally well-tolerated.
• Low-dose immunotherapy (LDI): A form of ultra-low-dose antigen therapy aimed at down-regulating the immune response to Borrelia. Anecdotal reports are mixed, and controlled studies have not been published.
• Hyperbaric oxygen therapy (HBOT): Some patients report benefit, and small case series have been published. Borrelia is a microaerophilic organism, and the rationale is that high-oxygen environments may inhibit its growth. Controlled trials are needed.
• Biofilm-disrupting agents: Enzymes like nattokinase and lumbrokinase are used to disrupt Borrelia biofilms, which are thought to protect persister bacteria from both antibiotics and the immune system [14].

Co-Infection Treatment: Why Lyme Antibiotics Alone May Not Be Enough

Ixodes ticks don’t just carry Borrelia burgdorferi. They can transmit multiple pathogens in a single bite. If you’re not getting better on Lyme treatment alone, co-infections are one of the first things to investigate.

Babesia

Babesia is a malaria-like parasite that infects red blood cells. It does not respond to the antibiotics used for Lyme. Standard treatment is atovaquone plus azithromycin for 7-10 days in mild cases, though immunocompromised patients or those with severe disease may require combination therapy with clindamycin and quinine [15]. Symptoms that suggest Babesia include drenching night sweats, air hunger, hemolytic anemia, and high fevers.

Bartonella

Bartonella species cause a vasculitis-like syndrome with symptoms that can include subcutaneous nodules, stretch-mark-like skin lesions, ice-pick headaches, anxiety, irritability, and plantar foot pain. Treatment typically involves prolonged courses of antibiotics such as azithromycin, rifampin, or fluoroquinolones, often for 4-6 weeks or longer. Bartonella is notoriously difficult to eradicate, and relapse rates are high.

Anaplasma and Ehrlichia

These intracellular bacteria respond to doxycycline, which is why doxycycline is the preferred first-line agent for Lyme. Patients treated with amoxicillin for Lyme may miss a concurrent Anaplasma or Ehrlichia infection because beta-lactam antibiotics are not effective against them.

Putting Together a Treatment Plan

Effective Lyme disease treatment is rarely just about picking the right antibiotic. A comprehensive approach includes:

• Accurate staging: Early localized, early disseminated, and late Lyme each require different treatment strategies.
• Co-infection testing and treatment: Babesia, Bartonella, Anaplasma, and Ehrlichia should be investigated, especially in patients who don’t respond to Lyme-targeted therapy.
• Anti-inflammatory support: Omega-3 fatty acids, curcumin, and specialized pro-resolving mediators (SPMs) can help manage the inflammatory burden.
• GI support: Prolonged antibiotics disrupt the gut microbiome. Probiotics (particularly Saccharomyces boulardii during antibiotic therapy) and a fiber-rich diet help maintain gut integrity.
• Sleep optimization: Sleep disruption is common in Lyme patients and directly impairs immune function and recovery.
• Detoxification support: Herxheimer reactions (symptom flares caused by bacterial die-off) are common during treatment. Adequate hydration, binders like cholestyramine or activated charcoal, and supportive measures can help manage these reactions.

When to Seek Specialist Care

If you’ve completed a standard course of antibiotics and still feel significantly unwell after 4-6 weeks, it’s reasonable to seek care from a practitioner experienced in tick-borne diseases. This might be an infectious disease specialist, a Lyme-literate physician, or an integrative medicine doctor with experience in complex tick-borne illness. Look for someone willing to test for co-infections and take a thorough history rather than dismissing persistent symptoms.

Related Reading

• Lyme Disease: The Complete Guide (Pillar)
• Lyme Disease Testing: Why Standard Tests Miss So Many Cases
• Chronic Fatigue Syndrome Treatment: What Helps and What Doesn’t
• Mold Illness Symptoms: How to Tell If Mold Is Making You Sick
• IV Therapy Benefits and Risks: What the Evidence Actually Shows

References

1. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis, and treatment of Lyme disease. Clin Infect Dis. 2021;72(1):e1-e48. doi:10.1093/cid/ciaa1215
2. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134. doi:10.1086/508667
3. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135. doi:10.1586/14787210.2014.940900
4. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015;29(2):269-280. doi:10.1016/j.idc.2015.02.004
5. Ljøstad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690-695. doi:10.1016/S1474-4422(08)70119-4
6. Koene R, Boulware DR, Gocke CD, et al. Lyme carditis: a systematic review. Clin Infect Dis. 2019;68(12):2073-2078.
7. Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? Qual Life Res. 2013;22(1):75-84. doi:10.1007/s11136-012-0126-6
8. Feng J, Auwaerter PG, Zhang Y. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One. 2015;10(3):e0117207. doi:10.1371/journal.pone.0117207
9. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85-92. doi:10.1056/NEJM200107123450202
10. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923-1930. doi:10.1212/01.WNL.0000071227.23769.9E
11. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992-1003. doi:10.1212/01.wnl.0000284604.61160.2d
12. Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374(13):1209-1220. doi:10.1056/NEJMoa1505425
13. Feng J, Leone J, Schweig S, Zhang Y. Evaluation of natural and botanical medicines for activity against growing and non-growing forms of B. burgdorferi. Front Med (Lausanne). 2020;7:6. doi:10.3389/fmed.2020.00006
14. Sapi E, Theophilus PA, Gundula-Gade K, et al. Effect of RpoN, RpoS and LuxS pathways on the biofilm formation and antibiotic sensitivity of Borrelia burgdorferi. Eur J Microbiol Immunol. 2016;6(3):225-236. doi:10.1556/1886.2016.00026
15. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46(3):370-376. doi:10.1086/525852